title: Our 2014 approach to breakthrough invasive fungal infections.
abstract: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.
authors: Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of the Charité University Medicine of Berlin, Potsdam, Germany.
authors: Georg
authors: G
authors: Maschmeyer
authors: Thomas F
authors: TF
authors: Patterson
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000935:Antifungal Agents
keywords: Breakthrough fungal infection; echinocandins; fluconazole; liposomal AmB; posaconazole; voriconazole